What is new in the 2024 Chinese guidelines for fatty liver disease?
作者信息
Yang Rui-Xu, Wong Vincent Wai-Sun, Fan Jian-Gao
机构信息
Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
Clin Mol Hepatol. 2025 Jul;31(3):e239-e246. doi: 10.3350/cmh.2024.1165. Epub 2025 Jan 21.
Abstract
摘要
相似文献
1
What is new in the 2024 Chinese guidelines for fatty liver disease?2024年中国脂肪肝疾病指南有哪些新内容？
Clin Mol Hepatol. 2025 Jul;31(3):e239-e246. doi: 10.3350/cmh.2024.1165. Epub 2025 Jan 21.
2
Steatotic liver disease: what role does alcohol consumption play?脂肪性肝病：饮酒起什么作用？
Minerva Med. 2025 Jul 17. doi: 10.23736/S0026-4806.25.09726-5.
3
Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).饮酒量和肌肉量对代谢功能障碍与酒精相关肝病（MetALD）及代谢功能障碍相关脂肪性肝病（MASLD）患者骨密度的影响。
Clin Nutr ESPEN. 2025 Jul 7;69:145-153. doi: 10.1016/j.clnesp.2025.07.002.
4
Dietary manganese intake is positively associated with metabolic dysfunction-associated steatotic liver disease: a multicohort study.膳食锰摄入量与代谢功能障碍相关脂肪性肝病呈正相关：一项多队列研究。
Eur J Nutr. 2025 May 26;64(5):188. doi: 10.1007/s00394-025-03708-8.
5
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.代谢功能障碍相关脂肪性肝病：肌肉与体重的故事。
World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346.
6
Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population-Based Study.代谢功能障碍相关脂肪性肝病、饮酒与心房颤动风险：一项基于全国人口的研究
J Am Heart Assoc. 2025 Jul 15;14(14):e042003. doi: 10.1161/JAHA.125.042003. Epub 2025 Jul 14.
7
Inappropriate Diet Exacerbates Metabolic Dysfunction-Associated Steatotic Liver Disease via Abdominal Obesity.不当饮食通过腹部肥胖加剧代谢功能障碍相关脂肪性肝病。
Nutrients. 2024 Dec 5;16(23):4208. doi: 10.3390/nu16234208.
8
The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities.中部地区肝脏研究联盟——优化肥胖相关肝病研究的合作伙伴关系：针对高发病地区和服务不足的社区。
NIHR Open Res. 2024 Dec 12;4:75. doi: 10.3310/nihropenres.13784.1. eCollection 2024.
9
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.糖尿病患者的代谢功能障碍相关脂肪性肝病（MASLD）：筛查与早期干预的必要性。美国糖尿病协会共识报告
Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094.
10
Steatotic liver disease arising in an asymptomatic 20-year-old man with panhypopituitarism and elevated transaminases.一名20岁无症状男性，患有全垂体功能减退症且转氨酶升高，出现了脂肪性肝病。
Can Liver J. 2024 Dec 19;7(4):511-516. doi: 10.3138/canlivj-2024-0030. eCollection 2024 Dec.
本文引用的文献
1
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.欧洲肝脏研究学会肝细胞癌管理临床实践指南
J Hepatol. 2025 Feb;82(2):315-374. doi: 10.1016/j.jhep.2024.08.028. Epub 2024 Dec 17.
2
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.代谢功能障碍与酒精性肝病（MetALD）：酒精性肝病专家小组立场声明
J Hepatol. 2025 Apr;82(4):744-756. doi: 10.1016/j.jhep.2024.11.028. Epub 2024 Nov 27.
3
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).《代谢功能障碍相关脂肪性肝病防治指南（2024年版）》
J Clin Transl Hepatol. 2024 Nov 28;12(11):955-974. doi: 10.14218/JCTH.2024.00311. Epub 2024 Nov 4.
4
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction.代谢功能障碍相关脂肪性肝病的药物治疗：进展与方向
Chin Med J (Engl). 2024 Nov 20;137(22):2687-2696. doi: 10.1097/CM9.0000000000003355. Epub 2024 Oct 29.
5
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
6
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.振动控制瞬时弹性成像评分预测脂肪性肝病患者的肝脏相关事件。
JAMA. 2024 Apr 16;331(15):1287-1297. doi: 10.1001/jama.2024.1447.
7
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
8
The global burden of fatty liver disease: the major impact of China.脂肪肝疾病的全球负担：中国的重大影响。
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):119-123. doi: 10.21037/hbsn-23-556. Epub 2024 Jan 12.
9
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.有过量饮酒史患者脂肪性肝病新命名法的验证：一项前瞻性队列研究数据分析
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):218-228. doi: 10.1016/S2468-1253(23)00443-0. Epub 2024 Jan 11.
10
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
Zotero 插件